News Celgene under pressure as growth slows Celgene has revealed disappointing Q3 results and scaled back forecasts for 2020, news which has caused its share price to plunge 18% yesterday.
News FDA puts hold on AZ and Celgene immunotherapy trials Regulator is exploring safety of immunotherapy combinations in blood cancer
News NICE recommends Celgene pancreatic cancer drug Abraxane finally gets NHS funding following price cut.
News Celgene hopes device + drug can tackle aggressive brain tumo... Novocure's Optune will be tested alongside investigational Celgene drug marizomib.
News Chinese CAR-T results offer hope of myeloma cure This year’s ASCO conference has plenty of data from the CAR-T therapy contenders - but little known Chinese biotech Nanjing Biotech looks to have trumped all the established firms.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.